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Abstract: We aimed to assess postprandial metabolic and appetite responses to a mixed-macronutrient
lunch following prior addition of whey protein to a carbohydrate-rich breakfast. Ten healthy males
(age: 24˘ 1 years; body mass index (BMI): 24.5˘ 0.7 kg/m2) completed three trials in a non-isocaloric,
crossover design. A carbohydrate-rich breakfast (93 g carbohydrate; 1799 kJ) was consumed with
(CHO + WP) or without (CHO) 20 g whey protein isolate (373 kJ), or breakfast was omitted (NB).
At 180 min, participants consumed a mixed-macronutrient lunch meal. Venous blood was sampled at
15 min intervals following each meal and every 30 min thereafter, while subjective appetite sensations
were collected every 30 min throughout. Post-breakfast insulinemia was greater after CHO + WP
(time-averaged area under the curve (AUC0´´180min): 193.1 ˘ 26.3 pmol/L), compared to CHO
(154.7 ˘ 18.5 pmol/L) and NB (46.1 ˘ 8.0 pmol/L; p < 0.05), with no difference in post-breakfast
(0–180 min) glycemia (CHO + WP, 3.8 ˘ 0.2 mmol/L; CHO, 4.2 ˘ 0.2 mmol/L; NB, 4.2 ˘ 0.1 mmol/L;
p = 0.247). There were no post-lunch (0–180 min) effects of condition on glycemia (p = 0.492),
insulinemia (p = 0.338) or subjective appetite (p > 0.05). Adding whey protein to a carbohydrate-rich
breakfast enhanced the acute postprandial insulin response, without influencing metabolic or appetite
responses following a subsequent mixed-macronutrient meal.
Keywords: whey protein; appetite; breakfast; glycemia; insulinemia
1. Introduction
There is a growing body of evidence implicating manipulation of meal macronutrient
content, in particular protein ingestion, on markers of metabolic health (for review see [1]). The
postprandial effects of dairy protein have been investigated extensively [2,3], and recent studies
point to whey protein in particular as having potentially advantageous effects such as reduced
postprandial glycemia [4,5] and lipemia [6], potentially mediated by an increased postprandial
insulin response [7,8]. Recent studies also suggest that whey protein may induce potentially beneficial
effects on appetite [9,10]. Despite the predominant use of fasting markers to determine disease risk
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in the clinical setting, the importance of the postprandial milieu including hyperglycemia [11] and
hyperlipidemia [12] is increasingly being recognized as an important indicator of cardiovascular
disease risk [13]. Thus, the use of sequential meal testing in individuals has a clear clinical utility,
particularly with regard to triglyceride metabolism [14].
Ingestion of whey protein has been shown to promote insulin secretion to a greater extent
than other proteins sources [15] in lean individuals, with a high concentration of branched-chain
amino acids, particularly leucine, and their fast rate of appearance as likely integral mediators [16,17].
The subsequent synthesis and secretion of the incretin hormones glucose-dependent insulinotrophic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in healthy subjects, due to the presence of
amino acids and peptides derived from whey protein digestion [18], also likely play an important role
in enhanced insulinemic response. Incretin hormones increase both fasting and postprandial insulin
release [19]; their presence, in concert with increased plasma insulin concentrations, may also lead to
appetite suppressive effects [20].
A number of studies have investigated the effects of whey protein when consumed prior to,
or alongside, a meal on postprandial glycemia in normal-weight [15,21], overweight [9] or diabetic
populations [22]. When whey protein (18.2 g) is ingested at the same time as a high glycemic index
lunch meal, a 21% reduction in glucose area under the curve (AUC) has been identified in type 2
diabetes patients [5]. A dose-dependent reduction in glucose AUC has also been shown in healthy
individuals [23]. Following consumption of whey protein 30 min prior to a meal, reductions in
glycemia have also been shown in healthy participants [4] and type 2 diabetes patients [24]. However,
the application of these data is reduced as the consumption of a preload approximately 30 min prior to
a meal does not necessarily reflect conventional eating habits of the free-living individual [25].
Studies have also regularly prescribed large doses of whey protein, which may not be practical
to consume and involve intake of relatively high amounts of additional energy; typically, doses of
up to 55 g [22] have been employed. Furthermore, these studies typically involve short observation
periods [26] and the observation of single meal responses [27]. The influence on subsequent feeding
and metabolism is also important to understand, as the macronutrient composition of a breakfast
meal has been demonstrated to influence the glycemic response following subsequent feeding [28] in
healthy individuals. Thus, investigating the potential second meal effects of whey protein inclusion on
glycemia, insulinemia, lipemia, and appetite may be important in identifying efficacious strategies to
prevent potential declines in metabolic health, while providing further insights into the supplemental
use of whey protein.
Therefore, the aim of this study was to determine the acute postprandial metabolic and appetite
responses following a carbohydrate-rich breakfast, with and without co-ingestion of whey protein, in
addition to responses following subsequent feeding.
2. Methods
2.1. Participants
Ten normal-weight male participants, free from metabolic disease, were recruited (mean ˘ SEM;
age: 24˘ 1 years; mass: 79.7˘ 1.2 kg; stature: 1.81˘ 0.02 m; body mass index (BMI): 24.5 ˘ 0.7 kg/m2).
Inclusion criteria included being recreationally active (>30 min of structured exercise, 5 times/week)
and aged 18–40 years. Participants were not eligible if they were taking medication or had a
history of metabolic disease, disordered eating or smoking. All participants provided written
informed consent prior to inclusion, and all procedures were approved by the Faculty of Health
and Life Sciences Research Ethics Committee, Northumbria University (Newcastle upon Tyne, United
Kingdom) in accordance with the Declaration of Helsinki. This trial was registered at clinicaltrials.gov
as NCT02414061.
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2.2. Experimental Design
A crossover design was implemented with three experimental conditions consisting of a
high-carbohydrate breakfast trial (CHO), a high-carbohydrate breakfast with added whey protein
trial (CHO + WP) and a no breakfast trial (NB). Participants attended the laboratory on three separate
occasions, separated by at least 72 h, and underwent all three conditions in random order. Prior to each
visit, dietary intake was controlled through provision of a meal that participants were instructed to
consume 12 h before arrival at the laboratory. This meal provided 1.0, 0.4 and 0.5 g/kg body mass of
carbohydrate, fat and protein, respectively (3171 kJ). Participants were also instructed to avoid strenuous
physical activity and to refrain from alcohol and caffeine consumption for 24 h prior to each visit.
Upon arrival at ~0800 h, a cannula was inserted into an antecubital vein, and a baseline blood
sample was collected (refer to 2.4 Blood Sampling and Analysis). Visual analogue scales (VAS) were also
completed in order to assess appetite sensations at baseline (see 2.5 Subjective Ratings). Participants
subsequently consumed one of two test breakfasts (CHO or CHO + WP) or ingested a reference bolus
of water (NB) and remained in a rested state. Postprandial blood samples were collected at 15 min
intervals for the first hour and every 30 min thereafter, while VAS were taken every 30 min throughout.
After 180 min, participants were provided with the same standardized composite lunch meal under all
conditions. Blood samples and VAS were subsequently collected at corresponding time points to the
post-breakfast samples (Figure 1).
Nutrients 2016, 8, 116  3 of 14 
 
each  visit,  dietary  intake  was  controlled  through  provision  of  a  meal  that  participants  were 
instructed to consume 12 h b fore arrival at the labo atory. This meal pr v ded 1.0, 0.4 and 0.5 g/kg 
body mass of carbohydrate, fat and protein, respectively (3171 kJ). Participants were also instructed 
to avoid strenuous physical activity and to refrain from alcohol and caffeine consumption for 24 h 
prior to each visit. 
Upon arrival at ~0800 h, a cannula was inserted into an antecubital vein, and a baseline blood 
sample was collected (refer to 2.4 Blood Sampling and Analysis). Visual analogue scales (VAS) were 
also  completed  in  order  to  assess  appetite  sensations  at  baseline  (see  2.5  Subjective  Ratings). 
Participa ts subsequ ntly consume  one of two  est breakfasts (CHO or CHO + WP)  r ing sted a 
reference  bolus  of water  (NB)  and  remained  in  a  rested  state. Postprandial  blood  samples were 
collected at 15 min intervals for the first hour and every 30 min thereafter, while VAS were taken 
every 30 min  throughout. After 180 min, participants were provided with  the same standardized 
composite lunch meal under all conditions. Blood samples and VAS were subsequently collected at 
corresponding time points to the post‐breakfast samples (Figure 1). 
 
Figure 1. Schematic  layout of experimental  trials. CHO: high‐carbohydrate breakfast  trial; CHO + 
WP: high‐carbohydrate breakfast with added whey protein trial; NB: no breakfast trial. 
2.3. Test Meals 
The  energy  content  and macronutrient  composition  of  the  test meals provided during  each 
trial are displayed  in Table 1. The breakfast meal given under CHO and CHO + WP consisted of 
white wheat  bread  (95  g)  and  strawberry  jam  (48  g) with  an  orange  juice  beverage  (200 mL), 
providing 1.2 g available carbohydrate/kg body mass (Table 1). In an effort to blind participants to 
the CHO and CHO + WP trials, 250 mL water was provided in an opaque bottle and flavored with 
10 drops  (approximately  0.5 mL)  of  energy‐free  vanilla  flavoring under CHO. This process was 
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consistency  of  the  liquid  due  to  the  presence  of  the  protein was  not  able  to  be  accounted  for. 
Participants may have been able to distinguish between these beverages; however, no reference was 
made  to which  trial was  being  conducted  throughout.  The whey  protein  powder  (Arla  Foods 
Ingredients  Group,  Viby,  Denmark)  had  a  protein  content  of  83%,  providing  20  g  protein  per 
serving which has previously been identified as an efficacious dose for reducing glycemia [4]. The 
relative protein content of the CHO + WP breakfast was 0.4 g/kg body mass  in comparison to 0.1 
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Figure 1. Schematic layout of experimental trials. CHO: high-carbohydrate breakfast trial; CHO + WP:
high-carbohydrate breakfast with added whey protein trial; NB: no breakfast trial.
2.3. Test Meals
The energy content and macronutrient composition of the test meals provided during each trial
are displayed in Table 1. The breakfast meal given under CHO and CHO + WP consisted of white
wheat bread (95 g) and strawberry jam (48 g) with an orange juice beverage (200 mL), providing 1.2 g
available carbohydrate/kg body mass (Table 1). In an effort to blind participants to the CHO and CHO
+ WP trials, 250 mL water was pr vided in an opaque bottle and flavo d w th 10 drops (approximately
0.5 mL) of energy-free vanilla flavoring under CHO. This process was repeate for the preparation
of breakfast under CHO + WP, where an identical breakfast was provided albeit with the addition of
24 g whey protein isolate, which was dissolved in the flavored water. These beverages were therefore
matched in terms of flavor; however, the difference in the consistency of the liquid due to the presence
of the protein was not able to be accounted for. Participants may have been able to distinguish between
these bev ages; owever, no reference was ma e to which trial was being co ducted throughout. The
whey protein powder (Arla Foods Ingredients Group, Viby, Denmark) had a protein content of 83%,
providing 20 g protein per serving which has previously been identified as an efficacious dose for
reducing glycemia [4]. The relative protein content of the CHO + WP breakfast was 0.4 g/kg body
mass in comparison to 0.1 g/kg body mass under CHO. Water was also provided alongside breakfast,
the volume of which was trial-dependent in order to st ndardize meal volumes across conditions.
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Under NB, a breakfast meal was not provided; however, an isovolumetric bolus (675 mL) of water was
consumed by participants at the applicable time point. Further water was not administered during the
postprandial period in order to maintain this standardization and control for any potential effects of
meal volume on appetite suppression. A timer was started upon initiation of consumption in all trials,
and participants were encouraged to consume the meal within 5 min.
Table 1. Energy and macronutrient composition of breakfast and lunch test meals.
Energy kJ (kcal) Carbohydrate g (E%) Fat g (E%) Protein g (E%)
CHO 1799 (430) 93 (87) 2 (4) 9 (8)
Breakfast CHO + WP 2172 (519) 95 (74) 2 (3) 29 (22)
NB 0 (0) 0 (0) 0 (0) 0 (0)
Lunch 3446 (824) 104 (50) 33 (36) 29 (14)
E%: percentage of total meal energy; CHO: high-carbohydrate breakfast trial; CHO + WP: high-carbohydrate
breakfast with added whey protein trial; NB: no breakfast trial.
An identical lunch meal was served at 180 min post-breakfast in all conditions. This consisted
of a standard portion of pasta (125 g) that was cooked and added to a tomato-based sauce (170 g)
along with cheddar cheese (40 g) and olive oil (15 mL) to provide 1.3, 0.4 and 0.4 g/kg body mass of
carbohydrate, fat and protein, respectively. Water (350 mL) was also served alongside the lunch meal,
and was withheld in the post-lunch period.
2.4. Blood Sampling and Analysis
At each collection point, a 10 mL sample of whole blood was drawn into a syringe from
an intravenous cannula (Venflon, BD Becton Dickinson Ltd., Franklin Lakes, NJ, USA). A 20 µL
capillary tube was filled with whole blood for immediate determination of glucose concentration by
an automated analyzer (Biosen C_line, EKF Diagnostics, Cardiff, UK), while the remaining blood was
transferred into an ethylenediaminetetraacetic acid (EDTA) tube (Vacutainer®, BD Becton Dickinson
Ltd., Franklin Lakes, NJ, USA) and centrifuged (10 min, 1734ˆ g, 4 ˝C). Plasma aliquots were stored
at ´80 ˝C for subsequent analysis. Following collection of each sample, the cannula was kept patent
through infusion of saline solution. Plasma insulin concentration was analyzed using a commercially
available enzyme-linked immunosorbent assay (ELISA) kit (IBL International, Hamburg, Germany),
while triglyceride, non-esterified fatty acid (NEFA) and glycerol concentrations were determined using
enzymatic colorimetric assays (Randox Laboratories, County Antrim, UK). Intra-assay coefficients of
variation (CV) were <10% for all biochemical analyses.
2.5. Subjective Ratings
Subjective appetite ratings were recorded at baseline and at 30 min intervals following both
breakfast and lunch meals using 100 mm paper-based VAS, which has been validated previously [29].
Scales were used to assess hunger, fullness, satisfaction and prospective food consumption, and
were anchored with extreme statements of opposite meaning at each end, i.e., “not at all full” and
“totally full”.
2.6. Statistical Analysis
Subjective appetite scales were measured from the extreme left of the scale to the point where
the participant had marked, in order to give a score in mm. All VAS were measured independently
by two researchers with the mean score used in all subsequent analysis. Values for hunger, fullness,
prospective consumption and satisfaction were used to calculate a combined appetite score by applying
Equation (1) as used previously [30]:
combined appetite score “ hunger` prospective consumption` p100´ fullnessq ` p100´ satisfactionq
4
(1)
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Time-averaged AUC data for the component aspects of subjective appetite were reported alongside
this composite measure.
AUC values were calculated for subjective appetite and blood analyte data using the trapezoidal
method for the post-breakfast (0–180 min) and post-lunch (180–360 min) periods [31], and these values
were subsequently time-averaged. Statistical analysis was conducted using the Statistical Package for
the Social Sciences (IBM SPSS; Version 21, Armonk, NY, USA). Baseline comparisons between trials and
AUC for all variables were assessed using one-way repeated measures analysis of variance (ANOVA).
The time point at 180 min post-breakfast was used as the baseline value for the post-lunch period. For
combined appetite score, data were presented as change from baseline, with subsequent calculation of
net incremental AUC (iAUC) [32]. Two-way repeated measures ANOVA (condition ˆ time) was used
to test for differences between plasma and appetite variables over time. Simple effects analysis was
performed upon identification of a significant interaction effect, and the Bonferroni post-hoc test was
used to correct the level of alpha for multiple comparisons. The level of statistical significance was set
at p < 0.05 and data are presented as mean ˘ SEM.
3. Results
3.1. Post-Breakfast Responses
Baseline measures for all variables were not different between trials (p > 0.05; Figures 2–4).
Post-breakfast plasma insulin concentrations are displayed in Figure 2a. There was a significant
condition ˆ time interaction (p < 0.001), condition effect (p < 0.001) and time effect (p < 0.001).
Concentrations peaked 30 min after breakfast consumption under CHO + WP and CHO, with both
similarly elevated above NB (p < 0.05) at 15–120 min post-breakfast, before returning to baseline levels.
Insulinemia across this period was greater under CHO + WP than CHO (time-averaged AUC0–180 min:
CHO + WP, 193.1 ˘ 26.3 pmol/L; CHO, 154.7 ˘ 18.5 pmol/L; p = 0.033), and was greater under both
breakfast trials than NB (46.1 ˘ 8.0 pmol/L; p < 0.001; Table 2).
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Figure 2. Mean ˘ SEM temporal changes in plasma insulin (a) and blood glucose (b) during the
post-breakfast period, and plasma insulin (c) and blood glucose (d) during the post-lunch period.
Significant differences (p < 0.05) between trials at individual time points are defined as follows: * NB vs.
CHO + WP and CHO, ** NB vs. CHO, *** NB vs. CHO + WP. CHO: high-carbohydrate breakfast trial;
CHO + WP: high-carbohydrate breakfast with added whey protein trial; NB: no breakfast trial.
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There was a significant condition ˆ time interaction (p < 0.001) and significant time effect
(p < 0.001) for blood glucose concentrations following breakfast consumption. Concentrations peaked
similarly 30 min after both breakfast meals (Figure 2b), with no change observed under NB (p > 0.05).
Blood glucose concentrations were not different between trials at 45–180 min post-breakfast (Figure 2b).
Furthermore, there were no differences in glycemia between conditions across the postprandial
period (Time-averaged AUC0–180 min: CHO + WP, 3.8 ˘ 0.2 mmol/L; CHO, 4.2 ˘ 0.2 mmol/L; NB,
4.2 ˘ 0.1 mmol/L; p = 0.247; Table 2).
Plasma concentrations of triglyceride, NEFA, and glycerol are presented in Figure 3. Triglyceride
responses were not different between trials across the postprandial period following breakfast
consumption (p > 0.05). NEFA concentrations were suppressed under CHO + WP and CHO in
comparison to NB at 90–180 min post-breakfast (p < 0.05), while glycerol was significantly lower
following CHO + WP than NB at 90–120 min post-breakfast (p < 0.05). NEFA time-averaged
AUC0–180 min was lower following both breakfast meals (CHO + WP, 0.13 ˘ 0.03 mmol/L; CHO,
0.13 ˘ 0.03 mmol/L) compared to NB (0.44 ˘ 0.08 mmol/L; p < 0.05; Table 2); however, triglyceride
(CHO + WP, 0.77 ˘ 0.13 mmol/L; CHO, 0.67 ˘ 0.07 mmol/L; NB, 0.66 ˘ 0.07 mmol/L; p = 0.334) and
glycerol (CHO + WP, 37 ˘ 7 µmol/L; CHO, 41 ˘ 5 µmol/L; NB, 57 ˘ 9 µmol/L; p = 0.092; Table 2)
responses were not different between trials.
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Figure 3. Mean ˘ SEM temporal changes in plasma triglyceride (a); NEFA (b) and glycerol (c) during
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* NB vs. CHO + WP and CHO, ** NB vs. CHO + WP. CHO: high-ca bohydrate breakfast trial; CHO +
WP: high-carb hydrate breakfast with added whey protein trial; NB: no breakfast trial.
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Table 2. Time-averaged areas under the curve for blood and plasma variables during post-breakfast
and post-lunch postprandial periods.
CHO + WP 1,2 CHO NB
Glucose (mmol/L)
Post-breakfast
AUC 3.8 ˘ 0.2 4.2 ˘ 0.2 4.2 ˘ 0.1
iAUC ´0.4 ˘ 0.1 ´0.2 ˘ 0.1 ´0.2 ˘ 0.1
Post-lunch
AUC 4.1 ˘ 0.1 4.0 ˘ 0.1 4.1 ˘ 0.2
iAUC 0.4 ˘ 0.2 ´0.0 ˘ 0.1 ´0.1 ˘ 0.2
Insulin (pmol/L)
Post-breakfast
AUC 193.1 ˘ 26.3 a 154.7 ˘ 18.5 b 46.1 ˘ 8.0 c
iAUC 120.2 ˘ 15.3 a 83.5 ˘ 8.6 b ´8.2 ˘ 2.8 c
Post-lunch
AUC 130.7 ˘ 18.8 136.9 ˘ 15.7 110.8 ˘ 18.6
iAUC 70.8 ˘ 11.1 74.2 ˘ 9.4 68.9 ˘ 13.5
Triglyceride (mmol/L)
Post-breakfast
AUC 0.77 ˘ 0.13 0.67 ˘ 0.07 0.66 ˘ 0.07
iAUC ´0.02 ˘ 0.03 0.00 ˘ 0.02 ´0.04 ˘ 0.02
Post-lunch
AUC 1.16 ˘ 0.16 a 0.99 ˘ 0.11 a 0.82 ˘ 0.10 b
iAUC 0.42 ˘ 0.05 a 0.39 ˘ 0.04 a 0.18 ˘ 0.05 b
NEFA (mmol/L)
Post-breakfast
AUC 0.13 ˘ 0.03 a 0.13 ˘ 0.03 a 0.44 ˘ 0.08 b
iAUC ´0.42 ˘ 0.13 ´0.35 ˘ 0.11 ´0.08 ˘ 0.05
Post-lunch
AUC 0.13 ˘ 0.02 a 0.18 ˘ 0.02 0.21 ˘ 0.02 b
iAUC 0.02 ˘ 0.02 a 0.01 ˘ 0.03 a ´0.35 ˘ 0.08 b
Glycerol (µmol/L)
Post-breakfast
AUC 37 ˘ 7 41 ˘ 5 57 ˘ 9
iAUC ´34 ˘ 15 ´30 ˘ 8 ´4 ˘ 4
Post-lunch
AUC 37 ˘ 6 45 ˘ 3 40 ˘ 7
iAUC ´9 ˘ 4 ´5 ˘ 6 ´26 ˘ 13
1 Values presented as mean ˘ SEM; 2 Labeled values with different lowercase letters on the same row
are significantly different between trials, p < 0.05. CHO: high-carbohydrate breakfast trial; CHO + WP:
high-carbohydrate breakfast with added whey protein trial; iAUC: net incremental area under the curve; NB:
no breakfast trial.
Temporal changes in subjective appetite following breakfast consumption are indicated by
incremental time course responses for combined appetite scores (Figure 4a). There was a significant
condition ˆ time interaction (p < 0.001), condition effect (p < 0.001) and time effect (p < 0.001).
Combined appetite scores were suppressed similarly under CHO + WP and CHO, with change from
baseline under both remaining below NB from 30 to 120 min post-breakfast (p < 0.05). Time-averaged
iAUC0–180 min for combined appetite score was greater under NB in comparison to CHO + WP and
CHO (p < 0.05; Table 3), with similar suppression observed under both breakfast trials (p > 0.05). This
observation is replicated for feelings of hunger, while prospective consumption iAUC0–180 min was
greater under NB in comparison to CHO + WP only (p = 0.004; Table 3).
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Figure 4. Mean ˘ SEM delta baseline changes in combined appetite score during the post-breakfast (a)
and post-lunch (b) periods. Significant differences (p < 0.05) between trials at individual time points
are defined as follows; * NB vs. CHO + WP and CHO, ** NB vs. CHO + WP. CHO: high-carbohydrate
breakfast trial; CHO + WP: high-carbohydrate breakfast with added whey protein trial; NB: no
breakfast trial.
Table 3. Time-averaged ar as under the curve for subjective ap ariables during post-bre kfast
and post-lunch postprandial periods.
CHO + WP 1,2 CHO NB
Combined appetite score (mm)
Post-breakfast
AUC 53.0 ˘ 3.9 a 55.4 ˘ 4.6 a 82.1 ˘ 2.5 b
iAUC ´23.1 ˘ 4.5 a ´18.4 ˘ 5.7 a 8.3 ˘ 0.8 b
Post-lunch
AUC 52.2 ˘ 4.8 57.4 ˘ 5.2 61.0 ˘ 5.7
iAUC ´16.4 ˘ 4.4 ´16.5 ˘ 3.5 ´28.2 ˘ 5.9
Hunger (mm)
Post-breakfast
AUC 48.7 ˘ 3.8 a 52.5 ˘ 4.3 a 74.5 ˘ 3.2 b
iAUC ´24.1 ˘ 4.4 a ´16.8 ˘ 5.7 a 9.8 ˘ 2.1 b
Post-lunch
AUC 48.7 ˘ 4.7 54.8 ˘ 5.0 57.3 ˘ 5.4
iAUC ´16.4 ˘ 4.6 ´17.0 ˘ 3.8 ´26.7 ˘ 5.7
Fullness (mm)
Post-breakfast
AUC 47.6 ˘ 4.0 a 46.1 ˘ 4.6 a 15.9 ˘ 2.4 b
iAUC 25. ˘ 4.7 a 23.1 ˘ 5.1 a ´8.9 ˘ 1.6 b
Post-lunch
AUC 49.2 ˘ 4.5 43.9 ˘ 5.5 39.2 ˘ 5.7
iAUC 17.3 ˘ 4.8 a 17.8 ˘ 3.4 30.8 ˘ 6.2 b
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Table 3. Cont.
CHO + WP 1,2 CHO NB
Prospective Consumption (mm)
Post-breakfast
AUC 58.1 ˘ 5.0 a 60.4 ˘ 6.0 a 85.0 ˘ 2.4 b
iAUC ´19.4 ˘ 5.0 a ´13.1 ˘ 7.3 6.8 ˘ 1.2 b
Post-lunch
AUC 56.8 ˘ 6.3 62.0 ˘ 5.7 65.4 ˘ 6.4
iAUC ´15.6 ˘ 4.6 ´14.3 ˘ 3.9 ´24.0 ˘ 6.4
Satisfaction (mm)
Post-breakfast
AUC 47.1 ˘ 3.5 a 45.4 ˘ 4.3 a 15.4 ˘ 2.5 b
iAUC 23.1 ˘ 5.0 a 20.7 ˘ 5.1 a ´7.8 ˘ 1.7 b
Post-lunch
AUC 47.6 ˘ 4.1 43.2 ˘ 5.1 39.7 ˘ 5.5
iAUC 16.1 ˘ 4.8 16.8 ˘ 3.5 31.1 ˘ 5.7
1: Values presented as mean ˘ SEM; 2: Labeled values with different lowercase letters on the same row
are significantly different between trials, p < 0.05. CHO: high-carbohydrate breakfast trial; CHO + WP:
high-carbohydrate breakfast with added whey protein trial; iAUC: net incremental area under the curve; NB:
no breakfast trial.
3.2. Post-Lunch Responses
Following lunch insulinemic and glycemic responses were not significantly different across all
trials (Figure 2c–d). There was no effect of condition or time ˆ condition interaction on plasma insulin
or blood glucose concentrations (p > 0.05). Postprandial time-averaged AUC also indicated that
insulinemia (CHO + WP, 130.7 ˘ 18.8 pmol/L; CHO, 136.9 ˘ 15.7 pmol/L; NB, 110.8 ˘ 18.6 pmol/L;
p = 0.283) and glycemia (CHO + WP, 4.1˘ 0.1 mmol/L; CHO, 4.0˘ 0.1 mmol/L; NB, 4.1 ˘ 0.2 mmol/L;
p = 0.509; Table 2) were not different throughout the 180-min period following consumption of a
subsequent meal.
Plasma triglyceride concentrations were elevated above NB responses under CHO and CHO +
WP at 90–150 min post-lunch (p < 0.05; Figure 3d). In contrast, no significantly different responses
were observed between trials for NEFA from 45 to 180 min post-lunch (p > 0.05; Figure 3e), with no
differences in plasma glycerol concentrations between trials throughout (p > 0.05; Figure 3f).
Deviations in subjective appetite responses between CHO + WP and CHO were not found
following lunch (p > 0.05; Figure 4b). Indeed, time-averaged iAUC was not different between
all conditions for the combined appetite score, in addition to the component measures of hunger,
prospective consumption, and satisfaction (p > 0.05; Table 3). Post-lunch fullness iAUC was greater
under NB than CHO + WP (p = 0.045), indicating more positive perception of this measure following
prior breakfast omission (Table 3).
4. Discussion
The aim of this study was to investigate the effect of supplementing a carbohydrate breakfast
with whey protein on metabolic and appetite responses acutely and following a subsequent meal.
The study was designed to reflect the practical application in a free-living setting; the amount of
whey, the timing of supplementation, and composition of meals were realistically achievable in the
context of habitual eating habits. We show that adding 20 g of whey protein to breakfast increases
the acute insulin response, without influencing glycemia, lipemia, or appetite sensations compared
to an identical meal without additional whey in young healthy males. Here, for the first time, it is
shown that adding 20 g of whey protein to breakfast does not alter glycemic, insulinemic, and appetite
responses to a subsequent lunch meal, compared to breakfast without whey, or fasting, in young males
free from metabolic disease.
Our observation of increased circulating insulin with whey protein supplementation reflects the
effect observed in a number of studies [7,8,15]. Potential mechanisms may center on the amino acid
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profile of whey itself, and its consequent incretin hormone stimulatory properties [20]. While we
detected a ~25% increase in post-breakfast (0–180 min) insulin AUC with the addition of whey to a
carbohydrate breakfast, this did not augment a significant effect on postprandial blood glucose. This
is contrary to the findings of previous studies, where various doses of whey protein have elicited
positive effects on acute glycemia in both healthy [7,33] and diabetic [5,22] populations. This may
partly be explained by insulin resistance being greater early in the morning following an overnight
fast [34], suggesting that the insulinotrophic effect was not strong enough to offset this. Whey protein
ingestion has also been shown to induce acute insulin resistance through impaired glucose disposal at
whole body level and across the leg [35], albeit in obese post-menopausal female participants. While
the mechanisms responsible for such an observation remain unclear, it is likely that any effects are
counterbalanced by the promotion of insulin secretion by protein ingestion. While it is possible the
dose of whey protein was insufficient to elicit a significant reduction in glycemia in healthy males, the
efficacious dose to affect insulin and post-meal glycemic response is reported to be as low as 10 g in
healthy individuals [4]. Following lunch, both glycemia and insulinemia were not affected by prior
whey consumption, indicating the priming effect of elevated pre-lunch insulin on pancreatic beta cells
may not have been substantial enough to alter post-lunch metabolism [36].
In the present study, whey protein supplementation did not affect subjective appetite. A number
of studies have previously reported no effect of whey protein consumption on satiety and subsequent
energy intake [37,38]. This is in contrast to other published observations, where consumption of whey
has enhanced satiety through a variety of proposed mechanisms, including increases in peak amino
acid, GLP-1, and cholecystokinin (CCK) concentrations in healthy females [9,39]. As energy intake was
not measured here, it is difficult to infer any direct effect that these sensations may have on subsequent
intake [40].
Cross-sectional studies have associated regular breakfast consumption with improved health
outcomes such as lower BMI and improved glycemic control [41,42]; however, few randomized
trials exist to support the causality of such associations, with recent studies suggesting no effect of
breakfast consumption on weight loss [43,44]. In the current study, breakfast omission did not affect
postprandial glucose or insulin concentrations following lunch. With regard to satiety, participants felt
fuller (relative to baseline) following lunch after prior breakfast omission compared to after the whey
protein-supplemented breakfast. This is surprising as breakfast omission has previously been shown
to negatively affect satiety responses to foods later in the day, with [45] or without [46] subsequent
increases in energy intake. The fact that participants were significantly less full at the lunch period
baseline (180 min post-breakfast) after breakfast omission meant that, although the change in fullness
from baseline was greater, this did not represent an absolute feeling of greater fullness. Breakfast
omission did not significantly affect any of the other subjective appetite indices in the post-lunch period;
similar circulating concentrations of insulin, which is considered a satiety hormone [47], reflected
this. Further research is required to establish whether participants would overcompensate in terms of
energy intake at a following meal regardless of subjective appetite ratings.
Measures of postprandial lipemia were similar between both breakfast trials throughout; however,
the omission of breakfast appeared to impact on post-meal lipid metabolism. NEFA was significantly
higher following breakfast omission, an effect that is likely mediated by the antilipolytic action of
insulin released in response to breakfast [48], and returned to similar levels to both breakfast trials
45 min after lunch. Elevated NEFA levels have previously been linked to metabolic dysregulation
and cardiovascular disease risk [49]; however, conversely, it has also been argued that they are
not necessarily associated with insulin resistance [50]. Plasma triglyceride concentrations were
significantly lower 90–150 min post-lunch following breakfast omission. It may have been concluded
that such a finding is related to the appearance of triglyceride in the plasma following prior breakfast
consumption [50]; however, the very low fat content of the breakfast (2 g) would suggest that the
handling of dietary fat from lunch (33 g) was affected by breakfast omission. As insulin concentrations
were not significantly different across conditions post-lunch, this suggests the reduction in plasma
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triglyceride concentration was not mediated by insulin-stimulated lipoprotein lipase activity. This
reduction may have implications when considering the current swathe of public opinion suggesting
that breakfast is the most important meal of the day. Our findings suggest that skipping breakfast on a
single occasion may not be detrimental to the response to foods consumed later that day, and may
provide beneficial effects on plasma triglyceride profile and, as mentioned above, subjective sensations
of fullness. Whether subsequent energy intake would be influenced remains to be established; however,
recent data indicates that the frequency, timing, and composition of meals consumed later in the day are
not different during six weeks of breakfast omission compared to regular breakfast consumption [43].
Metabolic responses in the longer term are still unclear, however, with such behavior potentially
leading to lower essential nutrient intakes over time.
The primary findings of the current study are contrary to the body of evidence that suggests whey
protein can provide acute advantages in postprandial handling of meals. There is a clear need for
studies investigating the effects of whey protein consumption at multiple meals so that findings can
be applied to a real world setting. Research has focused on the effects of prior meal composition on
responses to a subsequent meal, often termed the “second meal effect” [46,51,52]. In the present study,
glycemia was not significantly different across trials following lunch. Chronic supplementation may
be more efficacious when the aim is to positively affect the postprandial milieu throughout the day,
particularly as individuals spend the majority of the day in the postprandial state [13]. Further research
is also required to fully ascertain whether whey supplementation confers beneficial effects on metabolic
responses. Acutely, the promotion of greater insulin secretion following whey protein consumption
may have a glucose lowering effect [7,8,15]. Chronically, however, prolonged hyperinsulinemia in
normoglycemic conditions may decrease insulin sensitivity [53]. The acute increase in circulating
insulin observed in the present study may therefore be of benefit to individuals with type 2 diabetes;
however, the chronic effects in healthy, insulin sensitive individuals is less clear.
The breakfasts provided in the present study were not matched for energy content, and this may
limit the validity of direct comparisons between each meal. This was a consequence, however, of the
effort to ensure that this experimental manipulation had practical application, in an effort to mimic the
effect of “adding” a supplement to a meal, rather than replacing or substituting different components
of a meal.
5. Conclusions
In summary, we implemented an ecologically valid protocol to assess the effect of supplementing
a carbohydrate-rich breakfast with whey protein on metabolic and appetite responses, acutely and
following a subsequent meal. Whey protein addition to breakfast increased the insulinemic response to
that meal, without influencing metabolic or appetite responses to a subsequent mixed-macronutrient
lunch. Breakfast omission induced glycemic, insulinemic, and combined appetite responses to
a subsequent meal that, while maintaining lower circulating triglyceride, did not differ from
breakfast consumption.
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